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A single-domain antibody fragment in complex with RNase A:
non-canonical loop structures and nanomolar affinity using two
CDR loops
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Serge Muyldermans and Lode Wyns
Background: Camelid serum contains a large fraction of functional heavy-chain
antibodies — homodimers of heavy chains without light chains. The variable
domains of these heavy-chain antibodies (VHH) have a long complementarity
determining region 3 (CDR3) loop that compensates for the absence of the
antigen-binding loops of the variable light chains (VL). In the case of the VHH
fragment cAb-Lys3, part of the 24 amino acid long CDR3 loop protrudes from
the antigen-binding surface and inserts into the active-site cleft of its antigen,
rendering cAb-Lys3 a competitive enzyme inhibitor.
Results: A dromedary VHH with specificity for bovine RNase A, cAb-RN05,
has a short CDR3 loop of 12 amino acids and is not a competitive enzyme
inhibitor. The structure of the cAb-RN05–RNase A complex has been solved
at 2.8 Å. The VHH scaffold architecture is close to that of a human VH
(variable heavy chain). The structure of the antigen-binding hypervariable 1
loop (H1) of both cAb-RN05 and cAb-Lys3 differ from the known canonical
structures; in addition these H1 loops resemble each other. The CDR3
provides an antigen-binding surface and shields the face of the domain that
interacts with VL in conventional antibodies.
Conclusions: VHHs adopt the common immunoglobulin fold of variable
domains, but the antigen-binding loops deviate from the predicted canonical
structure. We define a new canonical structure for the H1 loop of
immunoglobulins, with cAb-RN05 and cAb-Lys3 as reference structures. This
new loop structure might also occur in human or mouse VH domains.
Surprisingly, only two loops are involved in antigen recognition; the CDR2
does not participate. Nevertheless, the antigen binding occurs with
nanomolar affinities because of a preferential usage of mainchain atoms for
antigen interaction.
Introduction
The conventional immunoglobulins consist of two heavy
and two light chains. A major fraction of the circulating,
functional antibodies of camelids, however, are homo-
dimers of heavy chains only [1]. The variable domain
mediating the antigen specificity of these special heavy-
chain antibodies is referred to as VHH and constitutes the
smallest known natural intact antigen-binding domain [2].
A considerable fraction of the enzyme-specific VHH
fragments rescued from an immunised dromedary act as
potent competitive enzyme inhibitors [3]. In contrast, only
a negligible fraction of antigen-binding fragments (known
as Fv = VH–VL; where VL depicts variable domains of
light chains) deriving from conventional antibodies have a
competitive enzyme-inhibiting activity. An example of a
dromedary VHH fragment acting as a competitive inhibitor
is cAb-Lys3. This VHH has an extraordinary 24 amino
acid long complementarity determining region 3 (CDR3)
loop that is restrained by a disulphide bond to the CDR1
region. The disulphide bond is a feature often encoun-
tered in the long CDR3 loops of camelid antibodies [4,5].
The crystal structure of cAb-Lys3 in complex with its
antigen, hen egg-white lysozyme, was solved previously
[6]. It showed that the CDR3 structure of cAb-Lys3 differs
markedly from any other CDR3 loop of conventional VH
domains [7,8]. Two parts with distinct functions are dis-
cerned in the CDR3 loop of cAb-Lys3 [6]. One part of the
loop is actively involved in antigen binding and provides
approximately 70% of the interacting surface. This stretch
protrudes from the antigen-binding site and penetrates
into the active-site cleft of the enzyme. The residues
inserting into the active-site cleft structurally mimic the
carbohydrate substrate of lysozyme. This explains why
cAb-Lys3 acts as a competitive enzyme inhibitor [9]. The
second part of the CDR3 loop folds over the face of the
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domain that would interact with a VL domain in conven-
tional Fv fragments. It partially shields a hydrophobic patch
from the solvent and increases the solubility of the VHH
in water [10].
For the VH domains of human, mouse and even cartilagi-
nous fish antibodies, the variability of mainchain conforma-
tions in both the first and the second hypervariable region
was found to be restricted to a limited number of conforma-
tions [11–15]. Thus, a set of canonical structures has been
defined for the exposed part of the first and second hyper-
variable loops (abbreviated as H1 and H2, respectively).
According to these studies, a loop adopts one of the canoni-
cal structures depending on its length and on the nature of
the residues present at certain key positions. This substan-
tially simplifies the modelling of the hypervariable loop
structures, as only a limited number of mainchain confor-
mations have to be considered [16].
Given the close sequence homology of the dromedary
VHH germline segments to human and dromedary VHs
[17], including the hypervariable regions, it is expected that
the hypervariable loops H1 and H2 adopt a VH-like canoni-
cal structure. The crystal structures of two camelid VHHs,
however, showed in each case an H1 loop deviating signifi-
cantly from the predicted canonical structure [6,18]. On the
basis of these crystallographic studies, we might question
the validity of canonical structures in camelid VHHs.
To analyse the mode of interaction of a dromedary VHH
with a shorter CDR3 loop and to investigate possible
deviations from the canonical loop structures, we selected
cAb-RN05 for structure determination. The cAb-RN05 is
a single-domain VHH that interacts with bovine RNase A
with nanomolar affinity. In contrast to cAb-Lys3, its
CDR3 loop has only 12 amino acids that are not restrained
by a disulphide bond and the antibody does not act as a
competitive inhibitor. The structure of the complex
between cAb-RN05 and its antigen, bovine RNase A, was
determined at 2.8 Å resolution. Only two of the three
hypervariable loops are interacting with the antigen.
Results and discussion
Identification of a VHH antibody fragment that is specific
for bovine RNase A 
We raised an immune response against bovine RNase A in
a dromedary (Camelus dromedarius). The RNase A titer was
comparable to that obtained for porcine α-amylase or car-
bonic anhydrase [3]. Cloning of the VHH repertoire in a
phage display vector [19,20] and isolating the RNase A
binders by ‘panning’ resulted in a clone that clearly
encoded a VHH. The expressed protein is referred to as
cAb-RN05. It contained the dromedary VHH-marker
amino acids Phe37, Glu44, Arg45 and Gly47, whereas a
VH has Val37, Gly44, Leu45 and Trp47 (Figure 1) [4,5].
(The Kabat numbering [21] is used throughout the text.)
At position 11 we observed a leucine. In dromedary VHH,
this position is usually occupied by a serine [4], but llama
VHHs often have leucine at this position [5,18].
The CDR3 loop of cAb-RN05 has a length of only 12
residues. This is short for a dromedary VHH, but a fraction
of VHHs carrying even shorter CDR3 loops were found in
the llama [5]. The CDR3 of cAb-RN05 contains no cys-
teine residues (Figure 1), which is consistent with llama
VHH sequences with a short CDR3 loop. Consequently, a
disulphide bond does not restrain the CDR3 loop.
The kinetic binding parameters of the cAb-RN05 and
bovine RNase A were measured by a biosensor, and a Kd
of 35 nM was calculated, which is in the same range as
that for other VHHs [3,20]. Many dromedary VHHs with
specificity for enzymes are competitive enzyme inhibitors.
The effect of cAb-RN05 on the enzymatic functionality of
bovine RNase A was assayed spectrophotometrically at
pH 7.4 using two different substrates. It appeared that the
presence of cAb-RN05 affected both the depolymerisation
of torula yeast RNA [22] and the hydrolysis of the di-
nucleotide UpA [23] by RNase A. The initial catalytic rate
measured with UpA dropped to about 20% of the rate
obtained with the free enzyme. However, 5′–3′ cUMP that
binds into the active site of RNase A does not compete
with cAb-RN05 for binding to RNase A in an enzyme
linked immunosorbent assay (ELISA; data not shown).
Therefore, cAb-RN05 is not expected to interact with the
active site of RNase A.
General structural features
Data with a high-resolution limit of 2.8 Å were collected
from the cAb-RN05–RNase A complex, and the structure of
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Figure 1
The amino acid sequences of cAb-RN05, cAb-Lys3 [6] and human Pot
VH [26]. The framework and CDR regions (top line) and amino acid
numbering (bottom line) as defined by Kabat [21] are indicated. The
exposed parts of the first and second antigen-binding loop (known as
H1 and H2, respectively) [13] are underlined. The C-terminal His6-tail
of cAb-RN05 is in lowercase letters.
the complex was solved by molecular replacement. Table 1
gives an overview of data quality and refinement parame-
ters. The final model contains four cAb-RN05–RNase A
complexes in the asymmetric unit, with a phosphate mol-
ecule bound in each of the RNase A active sites.
The maximum root mean square (rms) difference for all
Cα atoms between the RNase A molecules and the mol-
ecule used as a search model for molecular replacement
is 0.36 Å (calculated with the program LSQKAB [24]).
This is comparable to the estimated coordinate error
(Table 1). It argues for the absence of induced fit in the
RNase A moiety upon interaction with the dromedary
antibody fragment.
The rms differences between the four RNase A–cAb-RN05
complexes present in the asymmetric unit are also small
(below 0.2 Å for Cα atoms). Only one complex will there-
fore be described (Figure 2).
To compare the overall β-sheet scaffold of the dromedary
VHH we defined a ‘core’ by omitting the N-terminal
residue and the CDR regions which adopt different
conformations in different immunoglobulins. Thus, a
least-squares superposition between each copy of the 
cAb-RN05 antibody and cAb-Lys3 using the Cα positions
of residues 2–25, 36–51, 57–70, 78–95 and 102–113
(leaving out the N terminus, the CDR loops and a loop
disordered in cAb-Lys3) gave an rms deviation of 0.73 Å.
An rms deviation of 0.46 Å was found for a simultaneous
superposition of all five molecules using the program
POLYPOSE [25]. Simultaneous superpositions of the four
cAb-RN05 molecules and a llama VHH antibody structure
published by Spinelli et al. [18] shows an rms difference of
0.27 Å for the same residues (excluding the four N-termi-
nal residues omitted in the llama VHH model).
The rms difference between cAb-RN05 and the human
Pot VH antibody [26] is 0.69 Å for the Cα atoms exclud-
ing the CDR regions. In summary, we conclude that the
β sheet scaffold of camelid VHHs shares a common fold
with the human VH molecules. This corroborates previ-
ous results [6,18,27].
The ‘VL side’ of the VHH
The single-domain VHHs are not sticky, in contrast to
conventional VHs deprived of their VLs [10,20,28]. The
improved solubility behaviour is achieved by altering the
surface characteristics of the face that would interact with
the VL domain in normal VHs, without significant changes
in the backbone conformation [6,18]. The modifications
include the framework2 amino acid substitutions Val37→
Phe, Gly44→Glu, Leu45→Arg and Trp47→Gly. The effect
of these substitutions is augmented in cAb-Lys3 by a
repositioning of Glu39, Trp103 and Glu105 sidechains
[6]. Similarly to cAb-Lys3, we found that the sidechain of
Trp103 of cAb-RN05 is rotated around its Cβ–Cγ bond
compared with the position taken in classical VH domains.
In both VHHs the Trp103 residue stacks with Phe37 and
exposes its Nε to the solvent. In contrast to cAb-Lys3, we
could not detect any significant difference in sidechain
orientation for Glu39 and Glu105 in cAb-RN05 compared
with VHs. These residues take an orientation close to that
found in human VHs.
The hypervariable loop H1
An extensive analysis of sequences of human and mouse
antibodies combined with information from the available
antibody crystal structures lead to the identification of
canonical structures for the H1 loop (residues 27–31).
These canonical structures describe the positions of the
mainchain atoms of the loop [11–13,15]. Apparently, the
mainchain atoms of the H1 loop adopt one of the three
possible canonical structures depending on the length of
the loop and the residues present at key positions.
A type 1 canonical structure is predicted for H1 loops con-
taining five residues, with a glycine at position 26 giving a
sharp turn. Furthermore, a hydrophobic cluster — formed
by the sidechains of key amino acids at position 24 (Ala),
27 (Phe), 29 (Phe) and 34 (Met) — supports the base of the
loop structure. According to these criteria, the H1 region
of cAb-RN05 with Ala24, Gly26, Tyr27, Tyr29, Met34
(Figure 1) is expected to adopt the canonical structure type
1. The least-squares superposition of Cα atoms for residues
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Table 1
Data collection and refinement statistics.
Data statistics
All data (Å) 15.0–2.8
R factor (%) 11.1
completeness (%) 99.2
I/σ 8.5
multiplicity 3.8
Highest resolution shell (Å) 2.9–2.8 
R factor (%) 33.6
completeness (%) 98.2
I/σ 3.9
multiplicity 3.7
Refinement statistics
Number of reflections 25,412
Number of reflections in free set 1298
R (%) 22.4
Rfree (%) 28.5
Rall data (%) 22.5
Correlation coefficient Fo/Fc 0.894
Correlation coefficient free Fo/Fc 0.865
Correlation coefficient all data Fo/Fc 0.894
Geometry 
rms deviation bond lengths (Å) 0.006
rms deviation bond angles (°) 0.025
rms deviation planarity (Å) 0.020
ESU based on Rfree (Å) 0.430
ESU based on ML residual (Å) 0.279
24–35 of three camelid VHH structures and the type 1
canonical structure, however, shows how the H1 region
of cAb-RN05 markedly differs from the type 1 structure
(Figure 3a). Instead of the expected internal location, the
sidechain of Tyr29 is pointing outwards and away from the
centre of the loop. Tyr27 escapes from the central region of
the loop as well (Figure 3b). The sidechains of residues 27
and 29 therefore become more accessible for antigen inter-
action than in a type 1 structure. The sidechain of residue
Tyr31 fills the pocket vacated by residue 29. The loop
structure of the H1 region of cAb-RN05 is stabilised by the
stacking of Tyr27 and Tyr31 (Figure 3c).
Deviation of the H1 region from the known canonical
structures has also been described for the cAb-Lys3 struc-
ture [6]. The Cα positions of the cAb-Lys3 and cAb-RN05
structures are close to each other (Figure 3c). An rms dif-
ference of 0.79 Å was calculated for the Cα atoms of
amino acids 24–35 of cAb-Lys3 and cAb-RN05. Thus, we
introduce the new type 4 canonical structure for the main-
chain atoms of the H1 region, with the loop structures of
cAb-Lys3 and cAb-RN05 as reference. 
Three crucial questions arise at this point. What are the
determinants of the type 4 canonical structure? What is
their frequency of occurrence? Will they occur in human
or mouse VH structures?
The exact determinants for a type 4 structure are hard to
identify from the presently available structural informa-
tion, but a bulky hydrophobic residue at position 31 seems
to be required to complete the hydrophobic core of the
loop. In cAb-Lys3, the proline at position 31 has a similar
location to the Tyr31 of cAb-RN05, also filling the pocket
vacated by residue 29 (Figure 3c). In contrast, the orienta-
tion of Tyr27 is quite different between cAb-RN05 and
cAb-Lys3 (Figure 3c) with an exposed or buried location,
respectively. The position of this amino acid is probably
less important for the loop conformation.
The frequency of occurrence of large hydrophobic amino
acids (Pro, Tyr, Ile, Leu, Met, Trp and Phe) at position 31
in dromedary VHHs is about 7%. Only a fraction of the H1
loops of all camelid VHHs is expected, therefore, to adopt
the canonical structure type 4. In human and mouse VHs
the presence of this loop structure might even be lower.
Of all human and mouse VH sequences within the Kabat
database [21], only 1.4% and 0.9%, respectively, contain a
large hydrophobic group at position 31. This low occur-
rence might explain why this loop structure was not yet
364 Structure 1999, Vol 7 No 4
Figure 2
Stereoview of the complex of the camelid
single domain antibody fragment cAb-RN05
(yellow) with its antigen bovine RNase A
(grey). The H1, H2 and H3 regions are shown
in blue. The N and C termini of both proteins
are indicated. The internal disulphide bonds of
RNase A are shown in yellow. The picture was
generated with the program SETOR [41].
found in classical VHs. We feel, however, that the require-
ment of having a bulky hydrophobic residue at position 31
cannot be the sole determinant. Indeed, the H1 region of
the human Pot VH antibody with an isoleucine at position
31 folds into a bona fide canonical type 1 structure [15,26].
The occurrence of a type 4 structure might also be limited
to camelid VHH structures: the H1 region is adjacent to
the H3 loop, which has different structures in VHH and
VH domains. It is reported that the residue at position 94
also influences the canonical structure type 1 of the H1
loop [13]. An arginine residue nearly exclusively occupies
this position in human or mouse VHs, whereas camelid
VHHs contain preferentially an alanine residue [4,5].
Finally, the canonical structure type 4 has been observed
only for VHH antibodies bound to their antigen. The
possibility remains, therefore, that the type 4 structure is
induced upon antigen binding, with the loop reverting to a
type 1 canonical structure in the absence of the antigen.
The hypervariable loop H2
Canonical structures have also been identified for the H2
region. The hairpin loop from residue 52–56 varies in size
(five, six or eight amino acids) and composition, but only
four different conformations have been reported and are
referred to as canonical structures 1–4 [13,15].
The H2 loop of cAb-RN05 is predicted to adopt a canoni-
cal structure type 3 because it is composed of six residues
containing the landmark amino acids Gly54, Gly55 and
Arg71 [29]. The crystal structure reveals that the H2 loop
of cAb-RN05 adopts neither canonical structure type 2
nor type 3 (Figure 4b,c), the two types known for an H2
loop of six residues. It is clear that the hydrogen-bonding
pattern found for the cAb-RN05 H2 region deviates sub-
stantially from that of these reference structures. Only
two mainchain hydrogen bonds are internal to the H2
loop instead of the eight and seven in the canonical struc-
tures type 2 and 3, respectively (Figure 4). The apex of
the H2 loop of cAb-RN05 is shaped by a hydrogen bond
connecting Asp52 with Arg74, and one between the car-
bonyl group of Ser52a with the amide of Gly74 (Figure 4a).
Additionally, the Arg71, which normally supports the H2
loop of canonical structure type 3 [29], has a quite dif-
ferent orientation with respect to the corresponding loop
of cAb-RN05.
This new H2 loop conformation is certainly not induced
by protein contacts because it is not involved in RNase A
binding or crystal contacts. It can therefore be considered
as a free loop with a structure intrinsic for the cAb-RN05
sequence. On the other hand, the sequence of the H2 loop
of cAb-RN05 is rather unusual, with a stretch of four con-
secutive glycine residues (positions 53–56) preceded by an
aspartic acid and serine at positions 52 and 52a, respec-
tively. This particular sequence might allow for otherwise
forbidden mainchain conformations at the C-terminal end
of the H2 loop.
The comparison of the H2 loops of the three camelid
VHH structures shows that several architectures can be
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Figure 3
The conformation of the first antigen-binding loop. (a) The Cα
positions of the CDR1/H1 loops of four different antibody structures
are shown. cAb-Lys3 [6] and cAb-RN05 are in grey and yellow,
magenta represents a llama VHH [18]. Green represents the type 1
canonical structure [15] of Pot VH [26]. The numbers indicate the
position in the loop of key amino acid residues. (b) Superposition of
the CDR1/H1 loop of cAb-RN05 (yellow) and a canonical type 1
structure (Pot VH, in green) including the sidechains at positions 27, 29
and 31. (c) Overlap of the two type 4 canonical structures cAb-RN05
(yellow) and cAb-Lys3 (grey). The sidechain of amino acids at
positions 27, 29 and 31 are shown. The figures were produced with
SETOR [41].
encountered. A deviation from the predicted canonical
structure of the H2 loop has also been described for cAb-
Lys3. The H2 loop of cAb-Lys3 adopts a canonical struc-
ture, but the loop was identified as a type 2 structure,
whereas type 3 was predicted from its sequence [6]. The
H2 loop of the llama single-domain antibody [18] seems to
be canonical structure type 2A [15].
The hypervariable loop H3
The identification of canonical structures for the H3 loop
based on the structures and sequences of human and
mouse is difficult as this loop is too variable in length and
sequence [12,13]. Recent analyses of sequences and struc-
tures, however, unveiled common structural features for
H3 loops [15,16,30,31]. This led to the proposition of rules
relating the sequence to the conformation of the H3
regions. According to the present insights, the H3 region is
divided into a torso and a head of the loop. The torso com-
prises a kinked two-stranded antiparallel β sheet formed
by five residues at the N terminus of the loop starting
from position 92 and the six amino acids preceding
residue 104 at the C terminus of the loop. The remaining
residues of the H3 region belong to the head of the loop,
for which the structure prediction remains controversial.
The structure of the torso is more defined and two classes
were proposed depending on the nature of the amino
acid at position 94. A lysine or an arginine at this position
forms a salt bridge with Asp101. Together with a hydro-
gen bond between the carbonyl oxygen at position 100c
and the sidechain of Trp103, this causes the H3 loop to
form a bulge. In contrast, when the amino acid at posi-
tion 94 is neither lysine nor arginine but glycine, such as
in mouse Fab-fragment 4-4-20 [32], then the torso fails to
form the bulge [15]. Consequently, the CDR3 loop of
cAb-RN05 with an alanine at position 94 is predicted to
have a non-bulged torso. Inspection of the architecture
at the H3 region of the cAb-RN05 shows that this loop
deviates substantially from the predicted reference struc-
ture (Figure 5). 
We assume that this deviation originates from the addi-
tional structural role imposed on the CDR3 of the camel
single-domain antibodies. It was shown previously that the
C-terminal half of the CDR3 of cAb-Lys3 folds over the
‘VL side’ of the domain. This location of the CDR3 shields
hydrophobic amino acids of the ‘VL side’ from contacting
solvent. A comparison of the CDR3s shows how the shorter
CDR3 of cAb-RN05 takes an equivalent position to the
C-terminal half of the longer CDR3 loop of cAb–Lys3
(Figure 6). The residues covered completely or partially by
the H3 loop of cAb-RN05 were identified by looking for
increased solvent accessibility of residues after deleting
the H3 loop, as calculated with the program NACCESS
[33]. These residues are Val2, Tyr31, Tyr33, Phe37, Arg45,
Ala50 and Leu59, with a difference in accessible surface
area of 35.0, 21.4, 88.4, 64.6, 32.3, 19.8 and 62.3 Å2, respec-
tively. Residues Val2, Tyr31 and Tyr33 are in contact with
residues at the base of the H3 loop. Residue Ala50 con-
tacts residue Glu98 of the CDR3, Leu59 is close to Leu99,
Phe37 is in contact with Leu99 and Trp103, and Arg45
contacts Asp100. In VH structures of conventional (VH–VL)
antibodies, the residues at position 37 and 45 (valine and
leucine, respectively) are well conserved and provide
important hydrophobic interactions with the VL domain.
The surface of Leu45 exposed upon removal of the VL
domain is in the order of 100 Å2 [34].
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Figure 4
The conformation of the second antigen-binding loop. (a) The H2 loop
of cAb-RN05 from amino acid residues 50 to 58 is shown together
with the β strand containing Arg71. (b) The H2 loop of a canonical
structure type 3 of Pot VH [26] and the adjacent β strand containing
Arg71 are shown. (c) The H2 loop of a canonical structure type 2.
Here the adjacent β strand contains the key amino acid Ala71. The
hydrogen-bonding pattern formed by the mainchain atoms of the H2
loop is indicated by dotted lines, and is clearly different in cAb-RN05
compared to the canonical loop structures. The figures were produced
with SETOR [41].
Antigen–antibody interaction surface
A conventional antibody has up to six loops to interact with
its antigen, whereas the dromedary single-domain antigen-
binding fragment has only three loops available. To our
surprise, the complex formation between the cAb-RN05
and bovine RNase A involves only the H1 and H3 regions
of the antibody. The CDR2 loop is not in the vicinity of
the bound antigen (Figure 2) and as a consequence, the
area of the antigen interaction surface is small.  It was
calculated to involve approximately 570 Å2 (using the
program NACCESS [33], probe radius 1.4 Å). This is
277 Å2 less than the previously solved dromedary single-
domain antibody cAb-Lys3 in complex with its antigen
(Table 2). The difference can be attributed to the protrud-
ing part of the CDR3 in the latter (Figure 6). For compari-
son, we also calculated the interaction surface area for a
number of conventional antibodies in complex with a
protein — using the same program and the same parame-
ters (Table 2). It is immediately apparent that the surface
area of cAb-RN05 involved in antigen interaction is smaller
compared with that of VH–VL surfaces interacting with
proteinaceous antigens.
The cAb-RN05 binds specifically to its antigen with nano-
molar affinity despite the fact that only two loops are used
for antigen binding. We therefore analysed the paratope–
epitope contacts. Top views of the antigen-binding site and
of its complement are shown in Figure 7. Residues of cAb-
RN05 within 3.6 Å of the antigen, and therefore assumed to
be involved in antigen interaction, are Tyr27, Tyr31, Ile32,
Tyr33, Gly95, Gly96, Tyr97, Arg100b, Thr100c and Gly101
(Table 3). Allowing a more generous radius of 4.0 Å adds
residues Tyr29, Arg100 and Tyr100d to the list. In this case,
a total of 83 van der Waals interactions are observed. This
number is on average half of what is reported for Fv–
antigen interactions (for review, see [8]). The large majority
of contacts, however, are made through backbone atoms in
the cAb-RN05 antigen complex (Table 3). Only five out of
33 are sidechain–sidechain interactions. All other interac-
tions listed involve a mainchain atom from antigen, anti-
body, or both. In sharp contrast, sidechain contacts are
dominant in Fv–antigen interactions [8]. A similar conclu-
sion can be drawn for the direct hydrogen bonds. There
are seven direct hydrogen bonds between RNase A and
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Figure 5
Stereoview of the overlap of non-bulged torso CDR3 reference structure
(PDB entry code 1flr [32], in blue) and the CDR3 of cAb-RN05 (yellow).
Only the backbone atoms are shown for clarity. The hydrogen-bonding
pattern of the reference structure is indicated by dotted lines. The
position of amino acid residues 92, 97, 99 and 104 are indicated for
reference. The figure was generated with SETOR [41].
Figure 6
Comparison of the H3 loops of cAb-RN05 (yellow) and cAb-Lys3
(grey). The position of H1 is indicated. The protruding part of the
CDR3 loop of cAb-Lys3 involved in antigen interaction is denoted by
an arrow labelled ‘a’. The part of the loop that folds over the ‘VL’ side
of the domain is labelled ‘b’. The figure was made with SETOR [41].
Table 2
Solvent-excluded surface area of antibody for proteinaceous
antigen–antibody complexes. 
Antibody, antigen PDB file Area (Å2)
cAb-Lys3 (VHH), lysozyme 1mel 847
Hyhel5 (Fab), lysozyme 2iff 841
JEL42 (Fab), HPR 2jel 750
NC10 (Fv), neuraminidase 1a14 684
D11.15 (Fv), pheasant lysozyme 1jhl 622
D1.3 HEWL (Fab), lysozyme 1fdl 613
cAb-RN05 (VHH), RNase A 1bzq 570
cAb-RN05 (Table 3). Each of them involves mainchain
atoms, from the antigen (two), the antibody (four), or both
(one). The high proportion of mainchain contributions par-
tially explains the high affinity of cAb-RN05 for its antigen.
It can be argued that the entropic penalty for making con-
tacts with intrinsically more rigid mainchain atoms is
smaller than for sidechain atoms.
A remarkable feature of cAb-RN05 is the involvement of
residue Tyr27 in antigen binding. It appears from Table 3
and Figure 7 that Tyr27 is involved in a direct hydro-
gen bond with the RNase A mainchain amide atom of
Asn62, as well as in a number of van der Waals interac-
tions. The cAb-RN05–RNase A structure is the first to
show the involvement in antigen binding of a residue this
far upstream in the H1 loop. In this region in conventional
antibodies, the antigen interactions occur through residues
30–35 [35]. The large hydrophobic sidechain of Tyr27 in
conventional VH domains packs deeply into an internal
hydrophobic pocket and is therefore unavailable for antigen
interaction. We predict that an antigen interaction with the
amino acid at position 27 will occur frequently in camelid
VHH antibodies because the amino acid at this position is
far more variable in dromedary and llama VHH sequences
than in mouse or human sequences [5]. The higher vari-
ability argues for a selective advantage when a somatic
mutation is introduced around this position.
As stated above, the binding of cAb-RN05 to RNase A
influences the catalytic efficiency of the enzyme. However,
cAb-RN05 was not expected to bind into the active site of
the enzyme, as its binding is not impaired by 5′–3′ cUMP.
The crystal structure of the complex clearly confirms that
cAb-RN05 does not bind into the active site of RNase A.
The Thr70 residue of the RNase interacts with cAb-RN05
(Figure 7; Table 3) and this residue is part of the down-
stream subsite of RNase A involved in substrate binding
[36]. Interference of cAb-RN05 with substrate binding might
be responsible for the 80% enzymatic activity reduction.
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Table 3
Summary of the interactions between cAb-RN05 and RNase A
within 3.6 Å. 
cAb-RN05 RNase A Distance (Å) Interaction type
Direct hydrogen bonds
Tyr27 OH Gln60 O 2.60 SC–MC
Tyr27 OH Asn62 N 2.84 SC–MC
Ile32 N Asn62 Oδ1 2.88 MC–SC
Gly95 O Tyr73 OH 2.77 MC–SC
Gly96 O Thr70 Oγ1 2.52 MC–SC
Arg100b O Gly112 N 2.80 MC–MC
Thr100c O Tyr115 OH 2.93 MC–SC
Non-hydrogen bond contacts
Tyr27 Cε1 Gln60 O 3.23 SC–MC
Tyr27 Cζ Gln60 O 3.36 SC–MC
Tyr27 OH Asn62 Cβ 3.37 SC–SC
Tyr31 Cα Asn62 Oδ1 3.59 MC–SC
Ile32 Cδ1 Asn62 O 3.57 SC–MC
Ile32 Cδ1 Asn62 Cγ 3.48 SC–SC
Ile32 Cδ1 Asn62 Oδ1 3.30 SC–SC
Tyr33 Cδ2 Thr70 Oγ1 3.19 SC–SC
Gly95 C Tyr73 OH 3.34 MC–SC
Gly95 O Tyr115 OH 3.36 MC–SC
Gly95 Cα Tyr73 OH 3.13 MC–SC
Gly96 C Thr70 Oγ1 3.50 MC–SC
Tyr97 Cα Thr70 Oγ1 3.37 MC–SC
Tyr97 Cδ1 Thr70 N 3.50 SC–MC
Tyr97 Cδ1 Thr70 Oγ1 3.15 SC–SC
Arg100b O Glu111 C 3.52 MC–MC
Arg100b O Glu111 Cα 3.24 MC–MC
Arg100b O Glu111 Cβ 3.11 MC–SC
Thr100c O Tyr115 Cε 3.47 MC–SC
Thr100c O Tyr115 Cζ 3.57 MC–SC
Gly101 N Tyr115 Cε1 3.50 MC–SC
Gly101 N Tyr115 Cζ 3.53 MC–SC
Gly101 Cα Tyr115 Cγ 3.40 MC–SC
Gly101 Cα Tyr115 Cδ1 3.48 MC–SC
Gly101 Cα Tyr115 Cδ2 3.44 MC–SC
Gly101 Cα Tyr115 Cε2 3.59 MC–SC
The interacting atoms, their distance and mainchain (MC) or sidechain
(SC) contacts are indicated in the table.
Figure 7
Top views of (a) cAb-RN05 paratope and (b)
RNase A epitope. The CPK representation of
the antibody (a) is depicted in yellow, with the
CDR1 highlighted in light blue, the CDR2 in
cyan and the CDR3 in dark blue. The residues
marked in red are involved in hydrogen bonds
with the antigen. Atoms in brown are involved
in hydrophobic interactions (within 3.6 Å). The
RNase A molecule (b) is represented in grey.
Atoms involved in hydrogen bonds are marked
in red whereas those involved in hydrophobic
interactions are in brown. The interacting
residues and their numbering are identified. The
figure was made with Bobscript [42] and
rendered with Povray.
Biological implications
An important part of the humoral immune response of
camelids consists of heavy-chain antibodies (homodimers
of heavy chains only, devoid of light chains). The vari-
able region of these functional heavy-chain antibodies
(VHH) originates from a DNA recombination event
from dedicated germline segments. The VHH domains
never associate with a variable light domain. The single
domain VHHs of camelids therefore constitute the
minimal antigen-binding site. This is considered to be an
asset in medical or biotechnological applications, where
stability, solubility and a small size for improved biodis-
tribution or lowering the immunogenicity is important. It
was subsequently proven that a significant fraction of the
VHHs raised against enzymes function as competitive
inhibitors for those enzymes.
We have studied a VHH fragment, cAb-RN05, which is
specific for RNase A. This binder is not a competitive
enzyme inhibitor, but it reduces the enzymatic activity of
RNase A by 80%. The structure of cAb-RN05 con-
firmed that the β-sheet scaffold characteristic of the vari-
able domains of immunoglobulins is well maintained.
The antigen-binding loops topped on this core, however,
adopt conformations not yet observed in human or mouse
variable heavy domains. Our present understanding sug-
gests that the conformations of the first and second
antigen-binding loops found here can occur in classical
VH domains. Consequently, the currently defined canoni-
cal structures for the antigen-binding loops do not ade-
quately represent all possible structures.
Occasionally, reports are made of antibodies binding their
antigen with only one single domain, either the VH or the
VL. The cAb-RN05 goes one step further because only
two hypervariable antigen-binding loops (H1 and H3) par-
ticipate in antigen binding. As a result the surface area
involved in antigen interaction is remarkably small. Never-
theless, an affinity constant in the nanomolar range was
determined. This high affinity arises probably because the
antigen recognition process is accomplished by van der
Waals contacts and direct hydrogen bonds mediated
through a large majority of mainchain atoms. In sharp
contrast, the conventional antibodies, having a larger
antigen —interacting surface, bind proteinaceous antigens
predominantly through sidechain contacts. It seems,
therefore, that camel heavy-chain antibodies use a differ-
ent strategy to interact with antigen than the conventional
antibodies of human and mouse. 
Materials and methods
Immunisation and crystallisation
A dromedary was immunised with type XIIA bovine pancreas RNase A
(Sigma) according to Lauwereys et al. [3]. A library was constructed
using lymphocytes from this dromedary [20]. The library was panned
on immobilised antigen in wells of microtiter plates that had been pre-
treated with 0.25% glutaraldehyde in water. Bound phages were eluted
with 50 mM diethylamine. Periplasmic expression and immobilised
metal affinity chromatography (IMAC) purification of cAb-RN05 with a
C-terminal His6 tail was performed according to Lauwereys et al. [3].
The cAb-RN05–RNase A complex was prepared by mixing a 2.5 mg ml–1
solution of pure cAb-RN05 with a 2.5 mg ml–1 solution of bovine
RNase A (Sigma) and purified by gel filtration on Superdex-75 manu-
factured by Pharmacia) in PBS. Crystals were grown from a solution
of 5 mg ml–1 total protein concentration using 15–20% (w/v) PEG 8000
and 0.1 M potassium phosphate at pH 6.4 using the hanging-drop
vapour diffusion method.
Data collection
The crystals of the cAb-RN05—RNase A complex belong to the space
group p1, with unit-cell dimensions of a = 66.5 Å, b = 66.8 Å, c = 69.3 Å,
α = 91.4°, β = 117.3°, γ = 97.3°. A data set to 2.8 Å was collected on
a MarResearch (Hamburg, Germany) image plate system using mono-
chromatized CuKα radiation produced by a rotating anode generator
Rigaku RU-H2R. Primary data processing was done with the program
Denzo [37]. Scaling was done using the program scalepack. Data
quality statistics are given in Table 1.
Structure determination
The structure of the complex of the cAb-RN05 antibody with its antigen
RNase A was solved using the molecular replacement technique as
implemented in AMORE [38] using data between 8.0 and 3.0 Å.
Based on the self-rotation function we expected four complexes in the
asymmetric unit.
The structure used to find the RNase A molecules was retrieved from
the Protein Data Bank (entry code 1ruv). The highest maxima in the
rotation function were at 7.5, 6.9, 6.7 and 6.5 rms, with the next peak at
3.9 rms. After translation search and rigid-body refinement, the correla-
tion coefficient using only these four molecules was 0.383, with an R
factor of 49.0%.
Next, a molecular replacement search was carried out to find the VHH
antibody molecules. The cAb-Lys3 structure was used [6] (PDB entry
code 1mel) as a search model. Again, four maxima were found in the
rotation function, with peak heights of 6.3, 5.5, 5.5 and 5.0 rms, with
the next peak at 4.6 rms. The translation search for the four antibody
molecules was performed relative to the four RNase A molecules
already positioned in the asymmetric unit. Rigid-body refinement with
all eight molecules with the program X-PLOR produced a model with
an R factor of 42.5% and an Rfree of 43.0%.
Refinement
The model obtained from the molecular replacement procedure was
submitted to a simulated annealing procedure using X-PLOR [39].
During simulated annealing, strong NCS (noncrystallographic symme-
try) restraints were used for the four RNase A molecules, but not for the
antibody molecules as this made the refinement unstable (due to a
program bug). After simulated annealing, refinement was continued
with the program REFMAC in maximum likelihood mode [40], with
strong NCS restraints applied separately to the RNase A and the anti-
body molecules. The N terminus and the CDR loops expected to be
different from the search model were first omitted from the model and
remodelled afterwards. Bulk-solvent correction was done using the
standard REFMAC algorithm. The final model contains residues 1 to
124 for all four RNase A molecules, and residues 1 to 124 for the anti-
body structures. Each RNase A molecule has a phosphate bound to its
active site. The His-tag at the C terminus of the antibody molecules
could not be modelled. The final model has an R factor of 22.4% and
an Rfree of 28.5%. The R factor for all data is 22.5%. The refinement
statistics are given in Table 1. 
Accession numbers
The coordinates have been deposited in the PDB with accession code
1BZQ.
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